Robert Lorne Hopfner - Nov 5, 2025 Form 3 Insider Report for Evommune, Inc. (EVMN)

Role: Director, 10%+ Owner
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol: EVMN
Transactions as of: Nov 5, 2025
Transactions value $: $0
Form type: 3
Date filed: 11/5/2025, 08:05 PM
Previous filing: Jul 3, 2025
Next filing: Nov 12, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hopfner Robert Lorne	Director, 10%+ Owner	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	2025-11-05	0001551966

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVMN	Series Seed Preferred Stock							Nov 5, 2025	Common Stock	3.03K		By Trust	F1, F2
holding	EVMN	Series Seed Preferred Stock							Nov 5, 2025	Common Stock	839K		By NFLS Delta III Limited	F1, F3
holding	EVMN	Series Seed Preferred Stock							Nov 5, 2025	Common Stock	419K		By Pivotal bioVenture Partners Fund I, L.P.	F1, F4
holding	EVMN	Series A Preferred Stock							Nov 5, 2025	Common Stock	325K		By NFLS Delta III Limited	F3, F5
holding	EVMN	Series A Preferred Stock							Nov 5, 2025	Common Stock	909K		By Pivotal bioVenture Partners Fund I, L.P.	F4, F5
holding	EVMN	Series B Preferred Stock							Nov 5, 2025	Common Stock	241K		By NFLS Delta III Limited	F3, F6
holding	EVMN	Series B Preferred Stock							Nov 5, 2025	Common Stock	267K		By Pivotal bioVenture Partners Fund I, L.P.	F4, F6
holding	EVMN	Series C Preferred Stock							Nov 5, 2025	Common Stock	36.8K		By NFLS Delta III Limited	F3, F7
holding	EVMN	Series C Preferred Stock							Nov 5, 2025	Common Stock	36.8K		By Pivotal bioVenture Partners Fund I, L.P.	F4, F7
holding	EVMN	Series C Preferred Stock							Nov 5, 2025	Common Stock	295K		By Pivotal bioVenture Partners Fund II, L.P.	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2	The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3	Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4	Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F5	The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F6	The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F7	The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
F8	Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.